Thrive Future Habitats (523120)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Positive book value of ₹2.50 per share provides a small tangible asset base.
• Piotroski F-Score of 5/9 is not zero; it suggests at least some financial health indicators are in place.
• Reported profit growth of 288.89% hints at a possible improvement in profitability, although from a low/loss-making base.
• Personal care is a basic consumer category with recurring demand, should the company regain sales.

Concerns

• Sales growth of -87.30% and latest quarter sales of ₹0 Cr mean the core business is effectively not generating revenue.
• ROE of -28.48% and ROCE of -11.44% show continuing destruction of shareholder capital.
• P/B of 14.67 against book value of ₹2.50 means the market price is far above the tangible net asset value; there is no margin of safety.
• Current price of ₹36.67 is below the stated 52-week low of ₹72.00, with no dividend and no promoter holding disclosure, indicating high uncertainty.

AI Analysis

Thrive Future Habitats, despite its name, does not pass my first test: a business must be able to deploy capital to earn attractive returns. The numbers here are alarming. The latest quarter reports sales of ₹0 crore and net profit of ₹0 crore. Sales have collapsed by 87.30%. A company that once generated revenue is now idle, at least according to this data. ROE is -28.48% and ROCE is -11.44%, meaning every rupee retained in the business is currently being destroyed rather than compounded. The reported profit growth of 288.89% cannot comfort me because P/E is 0.00; with no meaningful earnings, that growth figure is likely a mechanical result from a loss-making base. Book value is ₹2.50 per share, yet the market prices the stock at ₹36.67. That is a price-to-book ratio of 14.67. Graham would ask: why pay nearly fifteen times net assets for a company that earns negative returns on those assets? There is no margin of safety. The Piotroski F-score of 5/9 is weak. There is no dividend, and promoter holding is shown as unavailable, so I cannot judge insider ownership. The market itself is telling me something: the current price of ₹36.67 is below the lower end of the 52-week range of ₹72.00 to ₹149.45. That is extraordinary deterioration. This is a personal-care company, an industry with stable demand, but stability does not help if the company has no current sales and no demonstrated competitive moat. I may be wrong, and a genuine turnaround can create value, but investing before seeing restored revenue and positive returns is speculation. With a ₹17 crore market cap, even small absolute changes can move the stock, but that is not my game. I will wait for evidence of a viable, profitable business.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer